Bibliografia UJ CM

1/7
Aleksandra Wieczorek, Carla Manzitti, Alberto Garaventa, Juliet Gray, Vassilios Papadakis, Dominique Valteau-Couanet, Katarzyna Zachwieja, Ulrike Poetschger, Ingrid Pribill, Stefan Fiedler, Ruth Ladenstein, Holger N. Lode.
Clinical phenotype and management of severe neurotoxicity observed in patients with neuroblastoma treated with dinutuximab beta in clinical trials.
Cancers
2022 : Vol. 14, nr 8, il., bibliogr. 33 poz., abstr., sum.
Autor korespondencyjny: Holger N. Lode.
Open Access Creative Commons Attribution License CC-BY 4.0.
e-ISSN: 2072-6694
AZ
ORG
AIF
IF: 5.200
Adres url:
Streszczenie w PubMed:
2/7
Alberto Garaventa, Ulrike Poetschger, Dominique Valteau-Couanet, Roberto Luksch, Victoria Castel, Martin Elliott, Shifra Ash, Godfrey C.F. Chan, Genevieve Laureys, Maja Beck-Popovic, Kim Vettenranta, Walentyna Balwierz, Henrik Schroeder, Cormac Owens, Maja Cesen, Vassilios Papadakis, Toby Trahair, Gudrun Schleiermacher, Peter Ambros, Stefania Sorrentino, Andrew D.J. Pearson, Ruth Lydia Ladenstein.
Randomized Trial of Two Induction Therapy Regimens for High-Risk Neuroblastoma : HR-NBL1.5 International Society of Pediatric Oncology European Neuroblastoma Group Study.
Journal of Clinical Oncology
2021 : Vol. 39, nr 23, s. 2552-2563
Autor korespondencyjny: Ruth Lydia Ladenstein.
p-ISSN: 0732-183X
e-ISSN: 1527-7755
AZ
ORG
AIF
IF: 50.739
Adres url:
Streszczenie w PubMed:
3/7
Ruth Lydia Ladenstein, Ulrike Poetschger, Dominique Valteau-Couanet, Juliet Gray, Roberto Luksch, Walentyna Balwierz, Victoria Castel, Shifra Ash, Maja Beck Popovic, Genevieve Laureys, Godfrey Chi-Fung Chan, Ellen Ruud, Kim Vettenranta, Cormac Owens, Henrik Schroeder, Peter F. Ambros, Sabine Sarnacki, Tom Boterberg, Holger N. Lode.
Risk factors in the HR-NBL-1/SIOPEN study in patients receiving dinutuximab beta (DB) based immunotherapy.
Journal of Clinical Oncology
2020 : Vol. 38, nr 15 suppl., abtr. 10536
2020 ASCO Annual Meeting I.
p-ISSN: 0732-183X
SZZ
SIF
Adres url:
4/7
Lydia Ruth Ladenstein, Ulrike Poetschger, Dominique Valteau-Couanet, Juliet Gray, Roberto Luksch, Walentyna Balwierz, Victoria Castel, Shifra Ash, Maja Beck Popovic, Genevieve Laureys, Godfrey Chi Fung Chan, Ellen Ruud, Kim Vettenranta, Cormac Owens, Henrik Schroeder, Hans Loibner, Peter F. Ambros, Sabine Sarnacki, Tom Boterberg, Holger N. Lode.
Randomization of dose-reduced subcutaneous interleukin-2 (scIL2) in maintenance immunotherapy (IT) with anti-GD2 antibody dinutuximab beta (DB) long-term infusion (LTI) in front-line high-risk neuroblastoma patients: Early results from the HR-NBL1/SIOPEN trial.
Journal of Clinical Oncology
2019 : Vol. 37, nr 15, suppl., abstr. 10013
2019 ASCO Annual Meeting I.
p-ISSN: 0732-183X
SZZ
SIF
5/7
Ruth Ladenstein, Ulrike Poetschger, Martin Elliott, Roberto Luksch, Victoria Castel, Isaac Yaniv, Vassilios Papadakis, Genevieve Laureys, Josef Malis, Walentyna Balwierz, Ellen Ruud, Per Kogner, Henrik Schroeder, Ana Forjaz De Lacerda, Maja Beck Popovic, Pavel Bician, Miklos Garami, Toby Trahair, Andrew D.J. Pearson, Dominique Valteau Couanet.
Prognostic factors in stage 4 neuroblastoma treated with busulphan-melphalan: Report from the European HR-NBIA/Siopen trial.
Journal of Clinical Oncology
2016 : Vol. 34, nr 15 suppl., abstr. 10527.
2016 ASCO Annual Meeting, Chicago, 3-7 June 2016.
p-ISSN: 0732-183X
SZZ
SIF
6/7
Ruth Ladenstein, Ulrike Poetschger, Roberto Luksch, Penelope Brock, Victoria Castel, Isaac Yaniv, Vassilios Papadakis, Genevieve Laureys, Josef Malis, Walentyna Balwierz, Ellen Ruud, Per Kogner, Henrik Schroeder, Ana Forjaz De Lacerda, Maja Beck-Popovic, Pavel Bician, Miklos Garami, Toby Trahair, Peter Ambros, Andrew D.J. Pearson, Dominique Valteau-Couanet, SIOP Europe Neuroblastoma Group.
Major results from the HR-NBL1/SIOPEN trial for high risk neuroblastoma.
Pediatric Blood & Cancer
2012 : Vol. 59, nr 6, s. 988-989, abstr. O069
44th Congress of the International Society of Paediatric Oncology (SIOP), London, United Kingdom, 5th-8th October, 2012
p-ISSN: 1545-5009
SZZ
SIF
7/7
Ruth Ladenstein, Ulrike Poetschger, Roberto Luksch, Penelope Brock, Victoria Castel, Isaac Yaniv, Vassilios Papadakis, Genevieve Laureys, Josef Malis, Walentyna Balwierz, Ellen Ruud, Per Kogner, Henrik Schroeder, Ana Forjaz De Lacerda, Maja Beck-Popovic, Pavel Bician, Miklos Garami, Toby Trahair, Andrew D.J. Pearson, Dominique Valteau-Couanet.
Busulphan-melphalan is the superior myeloablative therapy (MAT) for high-risk neuroblastoma: Results from the HR-NBL1/SIOPEN Trial.
Pediatric Blood & Cancer
2011 : Vol. 57, nr 5, s. 733, abstr. O103
43rd Congress of the International Society of Pediatric Oncology (SIOP) 2011, Auckland, New Zealand, 28th-30th October, 2011
p-ISSN: 1545-5009
SZZ
SIF
Wyświetl ponownie stosując format:

Wyświetl/ukryj etykiety | Wyświetlenie wyników w wersji do druku | Pobranie pliku do edytora | Nowe wyszukiwanie | Biblioteka Medyczna UJ